When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
LGND - Agenus: Multiple Milestones In The Second Half Of 2024
Ligand Pharmaceuticals Incorporated
2024-05-29 09:55:22 ET
Summary
Agenus Inc. is developing botensilimab and balstilimab for colorectal cancer, among other oncology indications.
The company's timeline for a Biologics License Application filing for BOT/BAL in CRC has been delayed, but an FDA meeting in July could be followed by a filing.
Agenus has secured a $75M upfront payment as part of a royalty financing agreement with Ligand Pharmaceuticals.